- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 31.08. | MICROBA LIFE SCIENCES LIMITED: 2026 Annual Report & Appendix 4E | 1 | ASX | ||
| 31.08. | MICROBA LIFE SCIENCES LIMITED: 2026 Appendix 4G | - | ASX | ||
| MICROBA LIFE SCIENCES Aktie jetzt für 0€ handeln | |||||
| 31.08. | MICROBA LIFE SCIENCES LIMITED: 2026 Corporate Governance Statement | - | ASX | ||
| 26.08. | Health Check: Genetic Signatures and Microba talk merger as BCAL crashes the romance | 1 | Stockhead | ||
| 31.07. | MICROBA LIFE SCIENCES LIMITED: Change of Director's Interest Notice - Pasquale Rombola | 1 | ASX | ||
| 31.07. | MICROBA LIFE SCIENCES LIMITED: Change of Director's Interest Notice - Prof Ian Frazer | 1 | ASX | ||
| 29.07. | MICROBA LIFE SCIENCES LIMITED: Cleansing Notice | - | ASX | ||
| 29.07. | MICROBA LIFE SCIENCES LIMITED: Application for quotation of securities - MAP | 1 | ASX | ||
| 29.07. | MICROBA LIFE SCIENCES LIMITED: Notification regarding unquoted securities - MAP | 1 | ASX | ||
| 29.07. | MICROBA LIFE SCIENCES LIMITED: Notification regarding unquoted securities - MAP | 1 | ASX | ||
| 29.07. | MICROBA LIFE SCIENCES LIMITED: Notification regarding unquoted securities - MAP | 1 | ASX | ||
| 29.07. | MICROBA LIFE SCIENCES LIMITED: Application for quotation of securities - MAP | 4 | ASX | ||
| 28.07. | MICROBA LIFE SCIENCES LIMITED: Completion of Share Purchase Plan | 1 | ASX | ||
| 24.07. | MICROBA LIFE SCIENCES LIMITED: Results of General Meeting | - | ASX | ||
| 20.07. | MICROBA LIFE SCIENCES LIMITED: Microba signs multi-year SYNLAB agreement | - | ASX | ||
| 16.07. | Microba Q4 FY26 slides: core testing surges 78%, breakeven eyed | 1 | Investing.com | ||
| 16.07. | Microba Q4 FY26 slides: core testing revenue surges 92% | 1 | Investing.com | ||
| 16.07. | MICROBA LIFE SCIENCES LIMITED: Q4 FY26 Quarterly Investor Presentation & Webinar | - | ASX | ||
| 16.07. | MICROBA LIFE SCIENCES LIMITED: Q4 FY26 Quarterly Activities Report & Appendix 4C | - | ASX | ||
| 14.07. | MICROBA LIFE SCIENCES LIMITED: Change in substantial holding | - | ASX |
1 2 3 Weiter >>
45 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| HEMAB THERAPEUTICS | 41,190 | 0,00 % | Gubra A/S: Gubra collaboration partner Hemab announces first participant dosed in Phase 1 clinical trial of HMB-003, an investigational therapy for the management of heavy menstrual bleeding | Today, Gubra announced that its partner Hemab Therapeutics has dosed the first healthy volunteer in its Phase 1 clinical trial evaluating HMB-003, an investigational therapy for the management of heavy... ► Artikel lesen | |
| SCRIBE THERAPEUTICS | 33,000 | 0,00 % | Biotech Stocks At 52-Week Highs - Scribe Therapeutics Continues Rise After Nasdaq Debut, Royalty Pharma, Haemonetics, 10x Genomics, Labcorp Holdings | WASHINGTON (dpa-AFX) - The following biotech stocks reached a 52-week high on August 20, 2026, driven by key catalysts such as new product launches and the prospective release of data from clinical... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 45,320 | 0,00 % | Biotech Options Buzz: UTHR, NMRA, EWTX | ||
| DYNE THERAPEUTICS | 17,110 | 0,00 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | ||
| SHATTUCK LABS | 6,010 | 0,00 % | Shattuck Labs, Inc.: Shattuck Labs Reports Second Quarter 2026 Financial Results and Recent Business Highlights | - Phase 1 clinical trial results for SL-325 demonstrated a favorable safety profile, a potentially best-in-mechanism immunogenicity profile, and durable DR3 blockade of TL1A binding, potentially enabling... ► Artikel lesen | |
| ABSCI | 9,650 | 0,00 % | Absci auf Morgan Stanley Healthcare-Konferenz: KI-Plattform im klinischen Test | ||
| MBX BIOSCIENCES | 62,91 | 0,00 % | MBX Biosciences, Inc.: MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvuparatide in Adults with Hypoparathyroidism | Pivotal Phase 3 oPTimize trial design builds on positive Phase 2 Avail results and durable one-year clinical benefit Global registrational trial to enroll approximately 160 adults with HP to support... ► Artikel lesen | |
| TYRA BIOSCIENCES | 25,730 | 0,00 % | Tyra Biosciences (TYRA) Dabogratinib Delivers 57% Complete Response Rate in Phase 2 Trial. Is Phase 3 Supported? | ||
| QIAGEN | 38,410 | -0,51 % | AKTIE IM FOKUS: Qiagen ziehen an - Magazinbericht schürt Übernahmefantasie | FRANKFURT (dpa-AFX) - Bei den Aktien von Qiagen hat am Donnerstag ein Magazinbericht die bereits bestehende Übernahmefantasie angeheizt. Die Aktien des Molekulardiagnostik-Unternehmens zogen am Mittag... ► Artikel lesen | |
| ELECTRA THERAPEUTICS | 13,500 | +1,89 % | Electra Therapeutics, Inc.: Electra Therapeutics Announces Pricing of Upsized $350.0 Million Initial Public Offering | SOUTH SAN FRANCISCO, Calif., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Electra Therapeutics, Inc., a late clinical-stage biopharmaceutical company focused on pioneering a new class of precision medicines... ► Artikel lesen | |
| CABALETTA BIO | 2,550 | 0,00 % | Cabaletta Bio, Inc. - 8-K, Current Report | ||
| PRAXIS PRECISION MEDICINES | 299,28 | +0,11 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Extension Period for Relutrigine for Treatment of SCN2A and SCN8A Developmental and Epileptic Encephalopathies | FDA sets updated PDUFA date of December 27, 2026 BOSTON, June 29, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS)... ► Artikel lesen | |
| CANDEL THERAPEUTICS | 10,850 | 0,00 % | Candel Therapeutics auf der H.C. Wainwright Konferenz: Fokus auf Prostatakrebs-Therapie | ||
| COGENT BIOSCIENCES | 31,480 | 0,00 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) | NDA supported by positive results from the APEX pivotal trial demonstrating clinically meaningful responses and evidence of disease modification in patients with AdvSM PDUFA target action date set... ► Artikel lesen | |
| KYMERA THERAPEUTICS | 117,80 | +0,04 % | Kymera Therapeutics auf Morgan Stanley Konferenz: Offensive bei oralen Degradern |
Das Unternehmen MICROBA LIFE SCIENCES LIMITED kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,003 (-8,93 %) liegt der Kurs bei 0,026 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu MICROBA LIFE SCIENCES LIMITED finden Sie auf Wallstreet Online.